This column highlights the most useful biotechnology and pharmaceutical news and commentary from around the Web.
Los Angeles Times
Link: US Investigating CVS Prescription Refills
“The US Justice Department's civil fraud division is investigating claims that CVS Caremark
(NYSE:CVS) wrongly refilled prescriptions and billed insurers without the knowledge or the approval of its customers....The investigation also will look into whether CVS violated a $17.5-million settlement reached with federal authorities last year over allegedly falsified claims to Medicaid programs in California and nine other states...”
Link: Walgreens Must Refund Flu Shots
“The New York State Attorney General’s Office has reached a settlement with the Walgreen Co.
(NYSE:WAG) after an investigation determined that more than 3,000 people insured by the New York State Empire Plan were misled into thinking they were covered for flu shots administered at the pharmacy when they were not.”’
Link: Wells Fargo Analysts Upgrade Abbott Laboratories to 'Outperform'
“Analysts at Wells Fargo
(NYSE:WFC) upgraded pharmaceutical company Abbott Laboratories
(NYSE:ABT) from 'Market Perform' to 'Outperform' on Friday....”
Link: Bristol-Myers Squibb Offers a 4% Yield With a Significant Upside
(NYSE:BMY) currently offers a compelling, low-risk way of capitalizing on the next wave of pharmaceutical breakthroughs...this article will explore the three main disease state categories that will power BMY to future gains.”
Link: Eli Lillly’s Stomach-Cancer Drug Improves Survival
“Eli Lilly & Co.'s
(NYSE:LLY) experimental stomach cancer drug helped patients with advanced disease live longer, a study found. The shares rose....The most common side effects for the medicine, called ramucirumab, were high blood pressure, diarrhea and headache, the Indianapolis-based company said in a statement today.”
Link: GlaxoSmithKline Wins Supreme Court Tax Case
“The Supreme Court of Canada ruled on Thursday for GlaxoSmithKline Plc
(NYSE:GSK) in a tax case that centered on whether the drug conglomerate charged its Canadian subsidiary inappropriately high prices for ingredients so that it could avoid Canadian taxes.”
Link: Can Anything Stop Johnson & Johnson?
“Shares of Johnson & Johnson
(NYSE:JNJ) hit a 52-week high on Wednesday. Let's take a look at how it got there and see if clear skies are still in the forecast...Far removed from the instability of Europe's debt crisis and China's growth slowdown, J&J's cash flow continues to stream in uninterrupted, year-in and year-out.”
Link: Pfizer’s Inlyta Drug Misses Primary Endpoint
(NYSE:PFE) said a late-stage study of its drug Inlyta for the treatment of renal cell carcinoma didn't meet its primary endpoint.”
Link: FDA Panel Backs Sanofi SA, Isis Pharmaceuticals Inc. Drug for Rare Disorder
“Reuters reported that a US Food and Drug Administration panel of outside experts recommended Sanofi SA's
(NYSE:SNY) and Isis Pharmaceutical Inc's
(NASDAQ:ISIS) drug, Kynamro, for treatment of a rare genetic disorder that causes unusually high cholesterol and life-threatening cardiovascular disease...”
Link: Merck & Co and Theravance Sign $153 Million Cardio Pact
“Merck & Co
(NYSE:MRK) is linking up with Theravance
(NASDAQ:THRX) to develop treatments that target hypertension and heart failure....In exchange for granting the US giant a worldwide, exclusive license to its therapeutic candidates, Theravance will receive $5 million upfront, funding for research, and be eligible for milestone payments up to $148 million for the first indication.”
Wall Street Journal
Link: Watson’s Bottom Line to Get Lift From Actavis
“Generic drug maker Actavis is growing faster than the European sector, according to its chief executive, and is set to contribute at least €2 billion ($2.6 billion) in sales this year to US based Watson Pharmaceuticals
(NYSE:WPI), which bought the Switzerland based competitor earlier this year.”
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.